Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Inamoto Y, Pidala J, Chai X, Kurland BF, Weisdorf D, Flowers ME, Palmer J, Arai S, Jacobsohn D, Cutler C, Jagasia M, Goldberg JD, Martin PJ, Pavletic SZ, Vogelsang GB, Lee SJ, Carpenter PA; Chronic GVHD Consortium..

Arthritis Rheumatol. 2014 Apr;66(4):1044-52. doi: 10.1002/art.38293.

2.

Validation of measurement scales in ocular graft-versus-host disease.

Inamoto Y, Chai X, Kurland BF, Cutler C, Flowers ME, Palmer JM, Carpenter PA, Heffernan MJ, Jacobsohn D, Jagasia MH, Pidala J, Khera N, Vogelsang GB, Weisdorf D, Martin PJ, Pavletic SZ, Lee SJ; Chronic GVHD Consortium..

Ophthalmology. 2012 Mar;119(3):487-93. doi: 10.1016/j.ophtha.2011.08.040. Epub 2011 Dec 6.

3.

Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al.

Kuzmina Z, Joe GO, Baird K, Cowen EW, Naik HB, Steinberg SM, Curtis L, Comis LE, Pavletic SZ.

Arthritis Rheumatol. 2014 Sep;66(9):2646-8. doi: 10.1002/art.38697. No abstract available.

4.

Hand grip strength and 2-minute walk test in chronic graft-versus-host disease assessment: analysis from the Chronic GVHD Consortium.

Pidala J, Chai X, Martin P, Inamoto Y, Cutler C, Palmer J, Weisdorf D, Pavletic S, Arora M, Jagasia M, Jacobsohn D, Lee SJ.

Biol Blood Marrow Transplant. 2013 Jun;19(6):967-72. doi: 10.1016/j.bbmt.2013.03.014. Epub 2013 Mar 27.

5.

National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis.

Baird K, Steinberg SM, Grkovic L, Pulanic D, Cowen EW, Mitchell SA, Williams KM, Datiles MB, Bishop R, Bassim CW, Mays JW, Edwards D, Cole K, Avila DN, Taylor T, Urban A, Joe GO, Comis LE, Berger A, Stratton P, Zhang D, Shelhamer JH, Gea-Banacloche JC, Sportes C, Fowler DH, Gress RE, Pavletic SZ.

Biol Blood Marrow Transplant. 2013 Apr;19(4):632-9. doi: 10.1016/j.bbmt.2013.01.013. Epub 2013 Jan 20.

6.

Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

Pidala J, Kurland B, Chai X, Majhail N, Weisdorf DJ, Pavletic S, Cutler C, Jacobsohn D, Palmer J, Arai S, Jagasia M, Lee SJ.

Blood. 2011 Apr 28;117(17):4651-7. doi: 10.1182/blood-2010-11-319509. Epub 2011 Feb 25.

7.

Validation of the human activity profile questionnaire in patients after allogeneic hematopoietic stem cell transplantation.

Herzberg PY, Heussner P, Mumm FH, Horak M, Hilgendorf I, von Harsdorf S, Hemmati P, Rieger K, Greinix H, Freund M, Lee SJ, Holler E, Wolff D.

Biol Blood Marrow Transplant. 2010 Dec;16(12):1707-17. doi: 10.1016/j.bbmt.2010.05.018. Epub 2010 Jun 9.

8.

Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease.

Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ.

Biol Blood Marrow Transplant. 2014 Mar;20(3):337-44. doi: 10.1016/j.bbmt.2013.11.025. Epub 2013 Dec 4.

9.

Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead.

Krupski C, Jagasia M.

Curr Hematol Malig Rep. 2015 Sep;10(3):183-91. doi: 10.1007/s11899-015-0265-2. Review.

PMID:
26303672
10.

Measurement of oral chronic GVHD: results from the Chronic GVHD Consortium.

Treister N, Chai X, Kurland B, Pavletic S, Weisdorf D, Pidala J, Palmer J, Martin P, Inamoto Y, Arora M, Flowers M, Jacobsohn D, Jagasia M, Arai S, Lee SJ, Cutler C.

Bone Marrow Transplant. 2013 Aug;48(8):1123-8. doi: 10.1038/bmt.2012.285. Epub 2013 Jan 28.

11.

Sensitivity of changes in chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease Consortium.

Pidala J, Kurland BF, Chai X, Vogelsang G, Weisdorf DJ, Pavletic S, Cutler C, Majhail N, Lee SJ.

Haematologica. 2011 Oct;96(10):1528-35. doi: 10.3324/haematol.2011.046367. Epub 2011 Jun 17.

12.

National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.

Saillard C, Crocchiolo R, Furst S, El-Cheikh J, Castagna L, Signori A, Oudin C, Faucher C, Lemarie C, Chabannon C, Granata A, Blaise D.

Leuk Lymphoma. 2014 May;55(5):1106-12. doi: 10.3109/10428194.2013.820285. Epub 2014 Feb 4.

PMID:
23822538
13.

Predictors of survival, nonrelapse mortality, and failure-free survival in patients treated for chronic graft-versus-host disease.

Palmer J, Chai X, Pidala J, Inamoto Y, Martin PJ, Storer B, Pusic I, Flowers ME, Arora M, Pavletic SZ, Lee SJ.

Blood. 2016 Jan 7;127(1):160-6. doi: 10.1182/blood-2015-08-662874. Epub 2015 Nov 2.

14.

Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival.

Moon JH, Sohn SK, Lambie A, Ellis L, Hamad N, Uhm J, Gupta V, Lipton JH, Messner HA, Kuruvilla J, Kim D.

Biol Blood Marrow Transplant. 2014 Apr;20(4):556-63. doi: 10.1016/j.bbmt.2014.01.010. Epub 2014 Jan 18.

15.

Oral symptom intensity, health-related quality of life, and correlative salivary cytokines in adult survivors of hematopoietic stem cell transplantation with oral chronic graft-versus-host disease.

Fall-Dickson JM, Mitchell SA, Marden S, Ramsay ES, Guadagnini JP, Wu T, St John L, Pavletic SZ; National Institutes of Health Chronic Graft-versus-Host Disease Study Group..

Biol Blood Marrow Transplant. 2010 Jul;16(7):948-56. doi: 10.1016/j.bbmt.2010.01.017. Epub 2010 Feb 6.

16.

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.

Jacobsohn DA, Kurland BF, Pidala J, Inamoto Y, Chai X, Palmer JM, Arai S, Arora M, Jagasia M, Cutler C, Weisdorf D, Martin PJ, Pavletic SZ, Vogelsang G, Lee SJ, Flowers ME.

Blood. 2012 Sep 27;120(13):2545-52; quiz 2774. Epub 2012 Jul 6.

17.

The National Institutes of Health criteria for classification and scoring of chronic graft versus host disease: long-term follow-up of a single center series.

Tecchio C, Mosna F, Andreini A, Paoli L, Di Bella R, de Sabata D, Sorio M, Pizzolo G, Benedetti F.

Leuk Lymphoma. 2013 May;54(5):1020-7. doi: 10.3109/10428194.2012.733877. Epub 2013 Feb 19.

PMID:
23035648
18.

Validation of the National Institutes of Health chronic GVHD Oral Mucosal Score using component-specific measures.

Bassim CW, Fassil H, Mays JW, Edwards D, Baird K, Steinberg SM, Williams KM, Cowen EW, Mitchell SA, Cole K, Taylor T, Avila D, Zhang D, Pulanic D, Grkovic L, Fowler D, Gress RE, Pavletic SZ.

Bone Marrow Transplant. 2014 Jan;49(1):116-21. doi: 10.1038/bmt.2013.137. Epub 2013 Sep 2.

19.

Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults.

Theurich S, Fischmann H, Shimabukuro-Vornhagen A, Chemnitz JM, Holtick U, Scheid C, Skoetz N, von Bergwelt-Baildon M.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD009159. doi: 10.1002/14651858.CD009159.pub2. Review.

PMID:
22972135
20.

The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.

Pidala J, Kim J, Anasetti C, Nishihori T, Betts B, Field T, Perkins J.

Haematologica. 2011 Nov;96(11):1678-84. doi: 10.3324/haematol.2011.049841. Epub 2011 Jul 26.

Supplemental Content

Support Center